GITNUXREPORT 2025

Supply Chain In The Life Science Industry Statistics

Life sciences supply chain growing, investing, digitizing, while facing disruptions challenges.

Jannik Lindner

Jannik Linder

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: April 29, 2025

Our Commitment to Accuracy

Rigorous fact-checking • Reputable sources • Regular updatesLearn more

Key Statistics

Statistic 1

The life sciences supply chain labor force is expected to grow by 14% through 2025, driven by automation needs

Statistic 2

The global life sciences supply chain market is projected to reach $11.4 billion by 2025, growing at a CAGR of 9.5%

Statistic 3

The adoption of AI in life sciences supply chain management is expected to grow at a CAGR of 42% through 2030

Statistic 4

The pharma cold chain logistics market is expected to reach $21 billion by 2027

Statistic 5

The global serialization market in pharmaceuticals is projected to reach $8 billion by 2024

Statistic 6

The global pharma supply chain will need to accommodate a CAGR of 8% for biologics products over the next decade

Statistic 7

The global market for cold chain logistics solutions is projected to grow at a CAGR of 11% through 2028

Statistic 8

The annual cold chain logistics market growth rate is projected at 10% through 2027

Statistic 9

Approximately 30% of pharmaceutical supply chains experienced disruptions due to COVID-19

Statistic 10

The average pharmaceutical supply chain has a lead time of approximately 55 days from manufacturing to delivery

Statistic 11

70% of life sciences companies experience supply chain visibility challenges

Statistic 12

About 80% of life sciences companies have experienced inventory management inefficiencies

Statistic 13

85% of supply chain executives in the life sciences sector cite cybersecurity as a major concern

Statistic 14

Over 40% of pharmaceutical supply chain delays are caused by customs clearance issues

Statistic 15

The average cost of supply chain disruption in the pharmaceutical industry is estimated at $15 million per incident

Statistic 16

50% of pharmaceutical companies report challenges in managing temperature-sensitive products

Statistic 17

The number of supply chain-related recalls in the pharmaceutical industry increased by 10% in 2022

Statistic 18

78% of life sciences companies view supply chain resilience as a top strategic priority post-pandemic

Statistic 19

65% of companies report inefficiencies due to manual data entry in supply chain processes

Statistic 20

Approximately 20% of pharmaceutical supply chains are still paper-based, increasing risk and inefficiency

Statistic 21

The average pharmaceutical product spends 10-15 days in customs, contributing to supply delays

Statistic 22

Approximately 35% of supply chain delays are due to vendor management issues

Statistic 23

47% of supply chain disruptions in life sciences are caused by demand variability

Statistic 24

65% of companies in the life sciences industry plan to invest in supply chain digitization within the next two years

Statistic 25

Cold chain logistics account for about 60% of the total pharmaceutical supply chain expenses

Statistic 26

Just 25% of life sciences companies have fully integrated supply chain data across functions

Statistic 27

The use of blockchain in pharma supply chains could reduce counterfeit drugs by up to 60%

Statistic 28

72% of life sciences companies are exploring sustainable packaging options to reduce environmental impact

Statistic 29

55% of life sciences companies have adopted or are planning to adopt IoT solutions for inventory and asset management

Statistic 30

Blockchain implementation in pharmaceutical supply chains can reduce counterfeit incidents by up to 55%

Statistic 31

58% of pharma companies utilize third-party logistics providers for critical supply chain functions

Statistic 32

60% of life sciences firms plan to increase their use of predictive analytics for demand forecasting

Statistic 33

40% of life sciences companies plan to implement AI-driven demand planning tools within the next year

Statistic 34

The serialization of all pharmaceutical products is expected to be achieved in 2025, with 95% compliance globally

Slide 1 of 34
Share:FacebookLinkedIn
Sources

Our Reports have been cited by:

Trust Badges - Publications that have cited our reports

Key Highlights

  • The global life sciences supply chain market is projected to reach $11.4 billion by 2025, growing at a CAGR of 9.5%
  • Approximately 30% of pharmaceutical supply chains experienced disruptions due to COVID-19
  • 65% of companies in the life sciences industry plan to invest in supply chain digitization within the next two years
  • Cold chain logistics account for about 60% of the total pharmaceutical supply chain expenses
  • The average pharmaceutical supply chain has a lead time of approximately 55 days from manufacturing to delivery
  • 70% of life sciences companies experience supply chain visibility challenges
  • The adoption of AI in life sciences supply chain management is expected to grow at a CAGR of 42% through 2030
  • Just 25% of life sciences companies have fully integrated supply chain data across functions
  • About 80% of life sciences companies have experienced inventory management inefficiencies
  • The pharma cold chain logistics market is expected to reach $21 billion by 2027
  • 85% of supply chain executives in the life sciences sector cite cybersecurity as a major concern
  • The use of blockchain in pharma supply chains could reduce counterfeit drugs by up to 60%
  • Over 40% of pharmaceutical supply chain delays are caused by customs clearance issues

As the global life sciences industry gears up for an $11.4 billion supply chain market by 2025, it faces a complex web of challenges and transformative opportunities driven by digital innovation, with over 70% of companies seeking smarter solutions to combat disruptions, cybersecurity threats, and inefficiencies.

Labor Force and Workforce Dynamics

  • The life sciences supply chain labor force is expected to grow by 14% through 2025, driven by automation needs

Labor Force and Workforce Dynamics Interpretation

As automation propels a 14% boost in the life sciences supply chain workforce by 2025, it underscores a transformative shift—where human expertise and machine precision must collaborate to ensure life-saving innovations reach those who need them most.

Market Size, Growth, and Market Segments

  • The global life sciences supply chain market is projected to reach $11.4 billion by 2025, growing at a CAGR of 9.5%
  • The adoption of AI in life sciences supply chain management is expected to grow at a CAGR of 42% through 2030
  • The pharma cold chain logistics market is expected to reach $21 billion by 2027
  • The global serialization market in pharmaceuticals is projected to reach $8 billion by 2024
  • The global pharma supply chain will need to accommodate a CAGR of 8% for biologics products over the next decade
  • The global market for cold chain logistics solutions is projected to grow at a CAGR of 11% through 2028
  • The annual cold chain logistics market growth rate is projected at 10% through 2027

Market Size, Growth, and Market Segments Interpretation

As the life sciences industry’s supply chain accelerates into a future where AI fuels growth at nearly 42%, cold chain logistics expands to over $21 billion, and serialization becomes a billion-dollar battleground, it's clear that staying ahead of this rapidly evolving, temperature-sensitive market is no longer just a matter of logistics—it's a strategic imperative for innovation and survival.

Operational Challenges and Risks

  • Approximately 30% of pharmaceutical supply chains experienced disruptions due to COVID-19
  • The average pharmaceutical supply chain has a lead time of approximately 55 days from manufacturing to delivery
  • 70% of life sciences companies experience supply chain visibility challenges
  • About 80% of life sciences companies have experienced inventory management inefficiencies
  • 85% of supply chain executives in the life sciences sector cite cybersecurity as a major concern
  • Over 40% of pharmaceutical supply chain delays are caused by customs clearance issues
  • The average cost of supply chain disruption in the pharmaceutical industry is estimated at $15 million per incident
  • 50% of pharmaceutical companies report challenges in managing temperature-sensitive products
  • The number of supply chain-related recalls in the pharmaceutical industry increased by 10% in 2022
  • 78% of life sciences companies view supply chain resilience as a top strategic priority post-pandemic
  • 65% of companies report inefficiencies due to manual data entry in supply chain processes
  • Approximately 20% of pharmaceutical supply chains are still paper-based, increasing risk and inefficiency
  • The average pharmaceutical product spends 10-15 days in customs, contributing to supply delays
  • Approximately 35% of supply chain delays are due to vendor management issues
  • 47% of supply chain disruptions in life sciences are caused by demand variability

Operational Challenges and Risks Interpretation

Despite the high stakes and mounting risks—from cybersecurity threats to customs bottlenecks—the life sciences industry's supply chains remain entangled in inefficiency and opacity, proving that in a world where health hinges on timely delivery, the real cure lies in embracing digital resilience.

Supply Chain Infrastructure and Efficiency

  • 65% of companies in the life sciences industry plan to invest in supply chain digitization within the next two years
  • Cold chain logistics account for about 60% of the total pharmaceutical supply chain expenses
  • Just 25% of life sciences companies have fully integrated supply chain data across functions
  • The use of blockchain in pharma supply chains could reduce counterfeit drugs by up to 60%
  • 72% of life sciences companies are exploring sustainable packaging options to reduce environmental impact
  • 55% of life sciences companies have adopted or are planning to adopt IoT solutions for inventory and asset management
  • Blockchain implementation in pharmaceutical supply chains can reduce counterfeit incidents by up to 55%
  • 58% of pharma companies utilize third-party logistics providers for critical supply chain functions

Supply Chain Infrastructure and Efficiency Interpretation

With 65% of life sciences firms eyeing supply chain digitization in the near future, it's clear that as pharmaceutical companies increasingly rely on blockchain to combat counterfeits and IoT for smarter inventory, the industry is not only aiming to revolutionize its logistical efficiency—while boldly exploring greener packaging—it's also recognizing that many still depend heavily on third-party logistics, highlighting a complex balancing act between innovation and tradition.

Technology Adoption and Innovation

  • 60% of life sciences firms plan to increase their use of predictive analytics for demand forecasting
  • 40% of life sciences companies plan to implement AI-driven demand planning tools within the next year
  • The serialization of all pharmaceutical products is expected to be achieved in 2025, with 95% compliance globally

Technology Adoption and Innovation Interpretation

As the life sciences industry races toward predictive analytics and AI-powered demand planning, the imminent serialization milestone underscores a relentless push for transparency, efficiency, and global compliance—making supply chain innovation not just strategic but essential.

Sources & References